TWD 16.9
(0.0%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 204.79 Million TWD | -24.3% |
2022 | 270.54 Million TWD | 187.62% |
2021 | 94.06 Million TWD | -45.73% |
2020 | 173.32 Million TWD | 0.0% |
2019 | 199.13 Million TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 37.66 Million TWD | 0.0% |
2024 Q1 | 37.66 Million TWD | 10.09% |
2023 Q4 | 34.21 Million TWD | 0.0% |
2023 FY | - TWD | -24.3% |
2023 Q3 | 34.21 Million TWD | -18.48% |
2023 Q2 | 41.97 Million TWD | 0.0% |
2023 Q1 | 41.97 Million TWD | -4.15% |
2022 FY | - TWD | 187.62% |
2022 Q4 | 43.79 Million TWD | 0.0% |
2021 FY | - TWD | -45.73% |
2020 FY | - TWD | 0.0% |
2019 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
GeneFerm Biotechnology Co., Ltd. | 231.09 Million TWD | 11.382% |
Easywell Biomedicals, Inc. | -85.5 Million TWD | 339.52% |
TTY Biopharm Company Limited | 1.52 Billion TWD | 86.566% |
Synmosa Biopharma Corporation | 1 Billion TWD | 79.698% |
Orient EuroPharma Co., Ltd. | 582.93 Million TWD | 64.869% |
Center Laboratories, Inc. | -175.17 Million TWD | 216.91% |
Tien Liang BioTech Co., Ltd. | 31.04 Million TWD | -559.598% |
Orient Pharma Co., Ltd. | 172.39 Million TWD | -18.792% |
InnoPharmax Inc. | -62.12 Million TWD | 429.672% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 126.67 Million TWD | -61.663% |
Excelsior Biopharma Inc. | -29.36 Million TWD | 797.307% |
DV Biomed Co., Ltd. | 407.64 Million TWD | 49.762% |
Foresee Pharmaceuticals Co., Ltd. | -912.16 Million TWD | 122.451% |
Handa Pharmaceuticals, Inc. | 802.78 Million TWD | 74.49% |
UniPharma Co., Ltd. | -16.25 Million TWD | 1359.948% |
Anxo Pharmaceutical Co., Ltd. | 131.31 Million TWD | -55.961% |
Alar Pharmaceuticals Inc. | 394.52 Million TWD | 48.091% |
Winston Medical Supply Co., Ltd. | 228.32 Million TWD | 10.307% |
Mercury Biopharmaceutical Corporation | -39.03 Million TWD | 624.65% |
Bioray Biotech Co., Ltd | 12.13 Million TWD | -1587.614% |
TSH Biopharm Corporation Limited | 99.35 Million TWD | -106.132% |